Holen Sie sich die Stockscreener-App
3.14
1.57%
-0.05
Handel nachbörslich:
3.10
-0.04
-1.27%
Schlusskurs vom Vortag:
$3.19
Offen:
$3.1
24-Stunden-Volumen:
213.61K
Relative Volume:
0.71
Marktkapitalisierung:
$319.57M
Einnahmen:
$4.28M
Nettoeinkommen (Verlust:
$-84.59M
KGV:
-3.7399
EPS:
-0.8396
Netto-Cashflow:
$-87.79M
1W Leistung:
-2.18%
1M Leistung:
+4.15%
6M Leistung:
+2.28%
1J Leistung:
+107.95%
1-Tages-Spanne:
$3.05
$3.195
1-Wochen-Bereich:
$3.05
$3.49
52-Wochen-Spanne:
$1.45
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.14 | 324.66M | 4.28M | -84.59M | -87.79M | -0.8396 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy - Greater Geneva Bern area
AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy - MSN
ACIU stock rallies 16.3% in a week: Here's what you need to know - MSN
Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News - Insider Monkey
5 Best Strong Buy European Stocks to Invest In - Insider Monkey
Resistance Check: Can AC Immune SA weather a recessionQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know - TradingView
Can AC Immune SA reach resistance levels soonWeekly Trade Summary & Safe Entry Zone Identification - baoquankhu1.vn
Fed Watch: Will AC Immune SA stock hit new highs in YEARTrade Entry Report & Low Risk Investment Opportunities - baoquankhu1.vn
April 2026's Most Promising Penny Stocks - Yahoo Finance
Leerink reiterates AC Immune stock rating on Lilly deal amendment By Investing.com - Investing.com Canada
Why AC Immune Stock Zoomed Almost 15% Higher Today - Yahoo Finance
Leerink reiterates AC Immune stock rating on Lilly deal amendment - Investing.com
AC Immune stock surges on amended Lilly collaboration deal - Investing.com
AC Immune stock surges on amended Lilly collaboration deal By Investing.com - Investing.com South Africa
AC Immune amends license and collaboration deal with Lilly - The Pharma Letter
AC Immune rises after amending licensing deal with Lilly - Seeking Alpha
AC Immune, Lilly Amend Morphomer Tau Alliance - Contract Pharma
AC Immune amends Lilly collaboration, plans tau drug studies By Investing.com - Investing.com South Africa
AC Immune Secures Amended Tau Drug Collaboration with Lilly, Adds CHF 10 Million Upfront - TipRanks
According to the latest revised agreement terms, AC Immune SA will receive a total upfront payment of 10 million Swiss francs. - Bitget
AC Immune (NASDAQ: ACIU) amends Lilly Tau deal with CHF 10m upfront - Stock Titan
AC Immune amends Lilly collaboration, plans tau drug studies - Investing.com
AC Immune announces amendment to Morphomer® tau license and collaboration agreement with Lilly - marketscreener.com
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly - The Manila Times
ACIU Technical Analysis & Stock Price Forecast - Intellectia AI
ACIU Stock Price, Quote & Chart | AC IMMUNE SA (NASDAQ:ACIU) - ChartMill
AC Immune (ACIU) director Zuegel reports options and RSU-based share stakes - Stock Titan
Exit Recap: Can AC Immune SA deliver consistent EPS growthWeekly Trend Report & Smart Investment Allocation Tips - baoquankhu1.vn
Is AC Immune (ACIU) outperforming other medical stocks this year? - MSN
Ideas Watch: What is the long term forecast for AC Immune SA stockRate Cut & Entry and Exit Point Strategies - baoquankhu1.vn
ACIU SEC FilingsAC Immune 10-K, 10-Q, 8-K Forms - Stock Titan
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
AC Immune FY 2025 Results: Eyeing ACI-7104 Catalysts - seekingalpha.com
Trading Recap: Will AC Immune SA stock hit new highs in YEAR2026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options - Stock Titan
AC Immune shows first brain images of TDP-43 pathology in trial - Investing.com India
ACIU Unveils Promising Phase 1 Data for TDP-43 PET Imaging - GuruFocus
AC Immune Presents First In vivo Images of Brain TDP-43 - GlobeNewswire
Aug Volume: Does AC Immune SA outperform in volatile markets2026 Price Momentum & Growth Oriented Trading Recommendations - baoquankhu1.vn
AC Immune (ACIU) CFO discloses common shares, RSUs and option grants - Stock Titan
AC Immune (NASDAQ: ACIU) director Monika Buetler details initial share and option holdings - Stock Titan
AC Immune (NASDAQ: ACIU) director reports initial Form 3 holdings - Stock Titan
[Form 3] AC Immune SA Initial Statement of Beneficial Ownership - Stock Titan
AC Immune (ACIU) CEO discloses equity and option holdings - Stock Titan
AC Immune (ACIU) director June Carl Howard details share and option stakes - Stock Titan
AC Immune (ACIU) Upgraded to Buy: Here's Why - Yahoo Finance
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):